Mithra and Adamed Sign Commercialization Agreement for Myring™ in the Czech Republic

  • Mithra grants non-exclusive 10-year license for vaginal contraception ring MyringTM to Adamed for commercialization in the Czech Republic
  • Agreement follows US and Austrian license granted to Mayne Pharma and Gynial, respectively
  • MyringTM to be manufactured at Mithra CDMO

Liège, Belgium, 27 December 2017 –  Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced a non-exclusive, 10-year license and supply agreement with Adamed Group (Adamed), for the commercialization of MyringTM, Mithra’s combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA), in the Czech Republic. Adamed is a Polish pharmaceutical and biotechnology company with a focus on gynaecology. Financial details of the agreement were not disclosed.